# Anavex Life Sciences Corp.: overview AVXL · Nasdaq · CIK 1314052 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/avxl.md) · [Financials](/companies/avxl/financials.md) · [Filings](/companies/avxl/filings.md) · [Insiders](/companies/avxl/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(0.14)](/filings/0001731122-26-000200.md) | [(0.13)](/filings/0001731122-26-001166.md) | [(0.16)](/filings/0001731122-26-001167.md) | not reported | [(0.06)](/filings/0001731122-26-000200.md) | [(0.06)](/filings/0001731122-26-001166.md) | [0.08](/filings/0001731122-26-001167.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.54)](/filings/0001731122-23-002197.md) | [(0.62)](/filings/0001731122-23-002197.md) | [(0.60)](/filings/0001731122-26-001164.md) | [(0.52)](/filings/0001731122-26-001164.md) | [(0.54)](/filings/0001731122-26-001164.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avxl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $20.9m | 8,055,628 | | Added +446,010 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.5m | 4,054,589 | | Added +190,639 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $7.9m | 3,046,538 | | Reduced −201,350 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $6.2m | 2,407,473 | | Added +219,198 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $5.0m | 1,922,770 | | Reduced −2,589,258 | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $2.8m | 1,071,809 | | Added +539,557 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $2.5m | 963,014 | | Added +206,222 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.5m | 948,633 | | Added +165,485 | | [Summit Financial, LLC](/funds/1765536.md) | 2026-06-30 | $2.4m | 909,430 | | Reduced −31,025 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $2.3m | 890,634 | | Added +86,199 | ## Recent filings [All 545 filings](/companies/avxl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 20:16 ET | [8-K](/filings/0001731122-26-001351.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001351 | | 2026-10-15 | 20:18 ET | [8-K](/filings/0001731122-26-001348.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001348 | | 2026-09-28 | 21:27 ET | [8-K](/filings/0001731122-26-001294.md) | 5.01 Change in control; 5.07 Shareholder vote results | 0001731122-26-001294 | | 2026-09-09 | 21:17 ET | [8-K](/filings/0001731122-26-001211.md) | 8.01 Other events | 0001731122-26-001211 | | 2026-09-02 | 21:06 ET | [8-K](/filings/0001731122-26-001179.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001179 | | 2026-08-28 | 20:28 ET | [10-Q](/filings/0001731122-26-001167.md) | Quarterly report, period 2026-06-30 | 0001731122-26-001167 | | 2026-08-28 | 20:26 ET | [10-Q](/filings/0001731122-26-001166.md) | Quarterly report, period 2026-03-31 | 0001731122-26-001166 | | 2026-08-28 | 20:25 ET | [10-Q/A](/filings/0001731122-26-001165.md) | Quarterly report, amended, period 2025-12-31 | 0001731122-26-001165 | | 2026-08-28 | 20:24 ET | [10-K/A](/filings/0001731122-26-001164.md) | Annual report, amended, period 2025-09-30 | 0001731122-26-001164 | | 2026-08-25 | 12:31 ET | [8-K](/filings/0001731122-26-001143.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001731122-26-001143 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001731122-25-001596.md), filed Nov 25, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1314052 - Tickers: AVXL - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Large accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.